Clinical Trials Logo

Clinical Trial Summary

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development of clinical disorders in patients with idiopathic REM Sleep Behavior Disorder (iRBD) and healthy controls.


Clinical Trial Description

REM sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment behaviors and REM sleep without muscle atonia (excessive EMG activity) during REM sleep.Increasing studies revealed that iRBD eventually converts to α-synucleinopathy, such as Parkinson's disease (PD), dementia with Lewy Bodies (DLB), and multiple system atrophy (MSA). Recent studies reported that over 80% of patients with iRBD eventually developed neurodegeneration at a mean interval of 14 years after iRBD onset or diagnosed. Thus, iRBD is regarded as a precursor of α-synucleinopathies. In addition to iRBD, a large series of other non-motor symptoms also present before the emergence of typical motor symptoms of PD, including autonomic dysfunction, olfactory loss, color vision impairment, neurocognitive impairment,neuroimaging of dopamine dysfunction, daytime sleepiness, and psychiatric disorders. In recent years, several longitudinal studies have found that patients with iRBD with a higher rate of these markers may have a faster progression of neurodegeneration. On the other hand, a variety of external risk factors of PD including environmental toxic exposure, lifestyle factors, and some medications have long been recognized, which affect numerous fundamental cellular processes by interaction with genetic predisposition. However, several knowledge gaps still need further studies to uncover. First, few studies have explored the predictive value of dynamic change of biomarkers in prodromal stage of PD. Second, few previous prospective studies also employed a control group to compare the change of these prodromal markers between patients and healthy controls over time. Third, as some of previous studies employed a retrospective study design, potential recall bias may contaminate the results. Moreover, the sample sizes of most previous studies investigating biomarkers were relative small (n < 80) and follow-up durations in most study are relatively short, which may have limited the statistical power to detect the risk factors with mild to moderate effect size. Finally, as previous reported longitudinal studies of iRBD mainly focused on Caucasian or other ethnic groups, there is only limited data about neurodegenerative biomarkers in Chinese iRBD. In conclusion, prospective longitudinal studies with larger sample size, regular follow-up, and relative long follow-up duration are needed to better map the progression of neurodegeneration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04048603
Study type Observational
Source Chinese University of Hong Kong
Contact Jihui Zhang, PhD
Phone (852)39197647
Email jihui.zhang@cuhk.edu.hk
Status Recruiting
Phase
Start date May 15, 2019
Completion date October 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT03671772 - Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
Recruiting NCT05109364 - Terazosin and Parkinson's Disease Extension Study Phase 2
Recruiting NCT03288909 - Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease
Completed NCT04006925 - Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate Phase 4
Completed NCT03353207 - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed NCT02824341 - Exploration of the Reward System by Functional MRI in Parkinson's Disease Patients With and Without REM Sleep Behavior Disorder N/A
Recruiting NCT03671798 - Establish a National Registry of REM Sleep Behavior Disorder
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Terminated NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Phase 2
Completed NCT03595475 - Prodromal Markers of First-degree Relatives of Patients With Psychiatric Disorders Comorbid With RBD
Recruiting NCT03660982 - Familial Aggregation and Biomarkers in REM Sleep Behaviour Disorder.
Completed NCT03255642 - Efficacy and Safety of Melatonin and Clonazepam for IRBD N/A
Recruiting NCT05904717 - Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder Phase 2
Not yet recruiting NCT06140511 - DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER
Recruiting NCT04386317 - Terazosin Effect on Cardiac Changes in Early Parkinson's Disease Phase 2
Enrolling by invitation NCT05514106 - MIBG in Aging and Neurologic Disorders Phase 4
Completed NCT03645226 - Gut Microbiota Across Early Stages of Synucleinopathy: From High-risk Relatives, REM Sleep Behavior Disorder to Early Parkinson's Disease
Recruiting NCT05262543 - PREdictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study
Recruiting NCT04071899 - French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP)
Completed NCT02708186 - Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Phase 2